The human epidermal growth factor receptor 2 (HER2; encoded by the ERBB2 gene) is a key regulator of cellular growth, division, and survival. When mutated or amplified/overexpressed, HER2 functions as an “on switch”, promoting uncontrolled proliferation and tumor progression. These genomic alterations drive the aggressive clinical behavior seen in HER2-positive cancers and are associated with high recurrence rates and poor outcomes.
This case study highlights validation of Champions’ TumorGraft3D models using clinically approved HER2-targeted ADCs, demonstrating they recapitulate established pharmacology as well as both target-dependent and independent cytotoxic effects.